文献速递细菌感染、耐药与抗菌药物

青霉素过敏住院患者直接口服激发试验:iNAAN国际研究

Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该前瞻性多中心国际实施研究在8国40家医院评估住院青霉素过敏患者直接口服激发(DOC)的安全性与实施效果。5121例评估者中1573例(30.7%)接受DOC,95.5%被取消过敏标签,仅0.4%发生严重不良事件。DOC组90天青霉素处方率显著更高(RR 13.25),WHO限制级抗生素处方更少(RR 0.73)。

要点

  • 住院青霉素过敏患者DOC安全,95.5%可取消过敏标签。
  • DOC使90天青霉素处方增加13倍,减少限制级抗生素使用。
  • 数字化工具结合审计反馈可促进DOC在多中心实施。

核心结论

  • 住院青霉素DOC多学科实施安全,显著改善青霉素处方并减少WHO限制级抗生素使用。

研究设计与样本

  • 成年住院青霉素过敏患者经数字化工具评估后接受DOC或仅评估,站点接受至少3个月的双月审计反馈。

主要发现

  • 5121例评估者中1573例(30.7%)接受DOC,其中1502例(95.5%)取消过敏标签。
  • 71例(4.5%)DOC阳性,6例(0.4%)发生严重不良事件。
  • 目标试验分析1852例中,DOC组892例,仅评估组960例。
  • 站点激活6个月内77名临床医生采用NAAN App。

临床怎么用

  • 对住院青霉素过敏患者可采用DOC以取消不必要的过敏标签,增加青霉素使用并减少广谱抗生素。
  • 结合数字化评估工具与定期审计反馈可促进DOC的推广实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 10% of hospitalized patients globally report a penicillin allergy, leading to inappropriate antibiotic prescribing and inferior healthcare outcomes. Evidence supporting the effectiveness and widespread implementation of inpatient penicillin direct oral challenge (DOC) is limited. METHODS: A prospective, multicenter, international type 2 hybrid effectiveness-implementation study was conducted in 40 hospitals across 8 countries between November 2022 and May 2025. Adult inpatients with a penicillin allergy underwent assessment using a digital penicillin allergy toolkit (National Antibiotic Allergy Network [NAAN] App). According to site clinical practice, participants received penicillin DOC (effectiveness intervention) or assessment only. Participating sites received bimonthly audit and feedback at least 3 months after site activation (implementation strategy). Observational data were used to emulate a target trial to examine secondary effectiveness outcomes, including antibiotic prescribing at 90 days in DOC versus non-DOC participants. The primary implementation outcome was adoption of the NAAN App within 6 months of site activation. RESULTS: Among 5121 participants assessed, 1573 (30.7%) underwent DOC, of which 1502 (95.5%) were delabeled. Of 71 (4.5%) participants with a positive DOC, 6 (0.4%) had a serious adverse event. Of 1852 inpatients in the target trial analysis, 892 underwent DOC and 960 underwent assessment only. Participants who underwent DOC were more likely to be prescribed penicillin (risk ratio [RR], 13.25 [95% confidence interval {CI}, 7.82-22.46]), and less likely to be prescribed World Health Organization (WHO) "Watch" or "Reserve" antibiotics (RR, 0.73 [95% CI, .60-.89]) at 90 days post evaluation. Within 6 months of site activation, 77 clinicians adopted the NAAN App. CONCLUSIONS: Multidisciplinary adoption of inpatient penicillin DOC was safe and significantly improved penicillin prescribing and reduced use of WHO restricted antibiotics.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mitri EA, Fletcher LR, Vogrin S, et al. Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study. Clin Infect Dis. 2026. PMID: 41921035. doi:10.1093/cid/ciag082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。